Longitudinal Analysis of Recurrence and Risk Factors of Early-Stage Resected Adenocarcinoma With Common EGFR Mutations: A Multicenter Retrospective Cohort Study in South Korea
Clinical Lung Cancer · 2025
DOI: 10.1016/j.cllc.2025.02.016 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von June Hong Ahn und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonology and Allergy, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Republic of Korea; Division of Pulmo…. Hauptthemen laut MEDLINE: Mutation, Neoplasm Recurrence, Local, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Despite curative surgery for lung cancer, 30% to 55% of patients experience recurrence or death, which highlights the importance of adjuvant treatment. Adjuvant osimertinib therapy effectively prolongs disease-free and overall survival in patients with lung cancer harboring common epidermal growth factor receptor (EGFR) mutations. To identify potential candidates for adjuvant osimertinib, it is crucial to understand the rates and identify risk factors of recurrence. METHODS: This multicenter, retrospective cohort study was conducted in the Republic of Korea and enrolled patients who, between 2010 and 2017, underwent resection of stages I-III adenocarcinomas, with common EGFR mutations. The primary outcomes comprised the rate and risk factors of postoperative recurrence. RESULTS: Among the 759 participants, the overall recurrence rate and median recurrence-free survival were 39.1% and 59.8 (interquartile range [IQR], 26.3-84.2) months, respectively, during a median follow-up of 73.0 (IQR, 55.4-95.0) months. The recurrence rates for stages IA, IB, IIA, IIB, IIIA, and IIIB were 14.7%, 45.5%, 53.8%, 72.5%, 80.3%, and 93.3%, respectively. Multivariate analysis revealed that age ≥ 65 years, body mass index < 18.5 kg/m², the Del19 subtype of EGFR mutation, tumor size ≥ 2.3 cm, N1 involvement, N2 involvement, predominantly micropapillary or solid pattern, and the presence of visceral pleural invasion were independently associated with recurrence. CONCLUSION: This multicenter cohort study demonstrated that stages I-III EGFR-mutated adenocarcinoma has a postoperative recurrence rate of 39.1%, and identified 7 independent risk factors for recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonology and Allergy, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Republic of Korea; Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medici…
- Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea; Lung Cancer Center, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.
- Division of Pulmonary Medicine, Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Republic of Korea.
- Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Republic of Korea.
- Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
- Department of Pathology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
Zitieren
APA
Ahn, J. H., Choi, S. H., Park, S. H., Kim, I., Park, J. H., Kim, J. Y., Kim, T. H., Lee, T., Cho, H. K., Jeong, J. H., Yang, J. W., Park, J. E., Kim, T. H., Lee, H. K., Lee, H. Y., Jung, H. J., Kim, J., Son, J., & Eom, J. S. (2025). Longitudinal Analysis of Recurrence and Risk Factors of Early-Stage Resected Adenocarcinoma With Common EGFR Mutations: A Multicenter Retrospective Cohort Study in South Korea. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.02.016
Vancouver
Ahn JH, Choi SH, Park SH, Kim I, Park JH, Kim JY, et al. Longitudinal Analysis of Recurrence and Risk Factors of Early-Stage Resected Adenocarcinoma With Common EGFR Mutations: A Multicenter Retrospective Cohort Study in South Korea. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.02.016
BibTeX
@article{Ahn2025,
author = {Ahn, June Hong and Choi, Sun Ha and Park, Sun Hyo and Kim, Insu and Park, Jin Han and Kim, Ji Yeon and Kim, Tae Hoon and Lee, Taehoon and Cho, Hyun Kyu and Jeong, Jong Hwan and Yang, Jung Wook and Park, Ji Eun and Kim, Tae Hun and Lee, Hyun-Kyung and Lee, Ho Young and Jung, Ho Jin and Kim, Jinmi and Son, Jungmin and Eom, Jung Seop},
title = {Longitudinal Analysis of Recurrence and Risk Factors of Early-Stage Resected Adenocarcinoma With Common EGFR Mutations: A Multicenter Retrospective Cohort Study in South Korea},
journal = {Clinical Lung Cancer},
year = {2025},
doi = {10.1016/j.cllc.2025.02.016}
}
EUVIMED